Kesaint Blanc Publishing is the leading foreign language-learning publisher in Indonesia, teaching Indonesian foreign languages since 1988. Kesaint Blanc Publishing has published other book genres as well, such as Children's Book. Our children's book showcases wonderful and fun stories accompanied by colorful and beautiful illustrations. We offer variety of stories for various age groups. All the titles are selected by their high educational and morale value.
View Rights Portal
Gulliver Editora emerged from a “trip”: discovering new worlds, discovering the beauty hidden in drawers, notebooks or computer files and presenting it to readers on paper or digital. Editing books is an adventure that is justified as these “treasures” are found and come to the public to enchant and transform the reader's world.
View Rights Portal
Book 2 in SUDEF Wildlife Detective series - Swahili - In this book , Sandeep, was excited to watch turtle eggs hatch at the beach with his grandfather. Now that the turtle eggs are disappearing, he and his friends have to solve the mystery because he promised his ailing grangfather to protect the eggs until they hatch.
Book 2 in SUDEF Wildlife Detective series - In this book , Sandeep, was excited to watch turtle eggs hatch at the beach with his grandfather. Now that the turtle eggs are disappearing, he and his friends have to solve the mystery because he promised his ailing grangfather to protect the eggs until they hatch.
Adventure series. Nurture and care for pet. Parent-child relations. Bathing a monkey. Clearing after your pet. With fun comes responsibility. Melisa Allela.
Adventure series. Nurture and care for pet. Parent-child relations. Bathing a monkey. Clearing after your pet. With fun comes responsibility. Melisa Allela.
Adventure series. Nurture and care for pet. Parent-child relations. Bathing a monkey. Clearing after your pet. With fun comes responsibility. Billy Mugambi.
Adventure series. Nurture and care for pet. Parent-child relations. Bathing a monkey. Clearing after your pet. With fun comes responsibility. Billy Mugambi.
To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)-a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)-face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them. This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: -To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks. -The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain. -What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]) - The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration -Identification of potential innovative solutions to the problem
